Page last updated: 2024-08-17

quinoxalines and Cardiomyopathy, Chagas

quinoxalines has been researched along with Cardiomyopathy, Chagas in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alves-Filho, JC; Baron, M; Cardozo, LE; Chevillard, C; Cunha, FQ; Cunha, TM; Cunha-Neto, E; Davoli-Ferreira, M; Dias, FC; Figueiredo, F; Frade, AF; Gava, FN; Hirsch, E; Lopes, CD; Lyroni, K; Medina, TS; Nakaya, HI; Sesti-Costa, R; Silva, GK; Silva, JS; Silva, MC; Tsatsanis, C1

Other Studies

1 other study(ies) available for quinoxalines and Cardiomyopathy, Chagas

ArticleYear
Canonical PI3Kγ signaling in myeloid cells restricts Trypanosoma cruzi infection and dampens chagasic myocarditis.
    Nature communications, 2018, 04-17, Volume: 9, Issue:1

    Topics: Adult; Animals; Biopsy; Cell Line; Chagas Cardiomyopathy; Class Ib Phosphatidylinositol 3-Kinase; Disease Models, Animal; Female; Heart; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Myeloid Cells; Myocardium; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Signal Transduction; Thiazolidinediones; Trypanosoma cruzi; Up-Regulation

2018